-

Cronus Pharma Announces the Launch of Florfinasone™ Otic for the Treatment of Otitis Externa in Dogs

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Cronus Pharma LLC, a fully integrated animal health company, today announced the launch of Florfinasone Otic (florfenicol, terbinafine, mometasone furoate), an FDA-approved product indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

Florfinasone Otic is a fixed-combination therapy that provides antibacterial, antifungal, and anti-inflammatory activity in a convenient single-use formulation. The product contains 16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride), and 2.2 mg/mL mometasone furoate. Proper patient selection is important when veterinarians consider the benefits and risks of using Florfinasone Otic. The integrity of the tympanic membrane should be confirmed before administering the product. Florfinasone Otic is not for use in cats.

"At Cronus Pharma, we are committed to delivering high-quality, cost-effective solutions that improve animal health outcomes and support veterinarians in clinical practice," said Janel Fisher, Vice President of Sales at Cronus Pharma. "The launch of Florfinasone Otic expands our portfolio with an effective treatment option designed to address susceptible bacterial, fungal, and inflammatory components commonly associated with canine otitis externa."

Florfinasone Otic combines three active ingredients with complementary mechanisms of action:

  • Florfenicol: A bacteriostatic antibiotic that acts by inhibiting protein synthesis.
  • Terbinafine: An antifungal agent that selectively inhibits the early synthesis of ergosterol.
  • Mometasone Furoate: A glucocorticosteroid with anti-inflammatory activity.

This product is approved by the U.S. Food and Drug Administration under ANADA #200-848 and is currently available in cartons of ten single-use dropperettes, with each dropperette containing 1mL dose for convenient administration.

Accessible to Veterinarians Nationwide
Cronus Pharma’s Florfinasone OTIC is available through national and regional distributors, making it convenient for veterinarians to access this important medication for canine otitis. Full product information is available from your veterinarian and should be reviewed prior to use. Our focus on quality and accessibility ensures that veterinarians and pet owners can trust our products.

About Cronus Pharma
Based in East Brunswick, New Jersey, Cronus Pharma is a privately held veterinary generic pharmaceutical company dedicated to advancing animal health. With integrated research, development, manufacturing, and marketing, we deliver innovative and cost-effective solutions for animals. Our passionate team of scientists is actively developing new products, with a robust pipeline awaiting FDA approval. Cronus Pharma is committed to supporting veterinarians and pet owners with high-quality, accessible solutions.

Learn more about our mission to enhance animal health at www.cronuspharmausa.com.

Contacts

Customer Service
Phone: 844-2-CRONUS (844-227-6687)
Email: contact@cronuspharma.com

Cronus Pharma LLC


Release Versions

Contacts

Customer Service
Phone: 844-2-CRONUS (844-227-6687)
Email: contact@cronuspharma.com

More News From Cronus Pharma LLC

Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Cronus Pharma LLC, a veterinary pharmaceutical company focused on developing high-quality, cost-effective animal health products, today announced the U.S. launch of Robenacoxib Injection, the only FDA-approved bioequivalent to ONSIOR® (robenacoxib) Injection. Robenacoxib Injection is indicated for the control of postoperative pain and inflammation associated with soft tissue surgery in dogs ≥ 4 months of age, and with orthopedic surgery, ovariohysterectomy...

Cronus Pharma Introduces Pimobendan Chewable Tablets (First FDA-Approved Generic) for Veterinary Use

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Cronus Pharma LLC, a leader in animal health innovation, is excited to announce the release of its new Pimobendan Chewable Tablets, available for purchase in the U.S. veterinary market after June 9, 2026. This product is designed to support veterinarians in providing high-quality cardiac care for dogs. It is the first FDA-approved bioequivalent of Vetmedin®. About Pimobendan Chewable Tablets Indicated for the management of mild, moderate, or severe congest...

Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Cronus Pharma LLC, a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company, announces the launch of Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution for immediate availability in the U.S. animal health market through national and regional distributors. "Butorphic is a vital analgesic for managing equine colic pain and we are excited to grow our equine portfolio. Importantly, Butorphic m...
Back to Newsroom